Observational studyMolecular diagnosis & therapy2025
Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction Cancer.
Observational study in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating tumor DNA in neoadjuvant therapy for solid tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent gastric or gastroesophageal junction cancers have poor prognoses and limited treatment options. While archival tumor tissue is commonly used for genomic profiling, it may not reflect molecular changes at recurrence.
objectiveWe aimed to assess the utility of a circulating tumor DNA analysis in identifying actionable genomic alterations at recurrence and compare findings with archival primary tumor profiles.
methodsThis prospective multicenter observational study included 50 patients with recurrent stage II or III gastric or gastroesophageal junction adenocarcinoma who had undergone curative surgery and adjuvant chemotherapy. A circulating tumor DNA analysis was performed using the Guardant360 assay at recurrence, and results were compared with comprehensive genomic profiling from archival primary tumor tissue when available. The primary endpoint was the detection rate of actionable genomic alterations in circulating tumor DNA, defined as those with an OncoKB level ≥ 3 in any cancer type.
resultsCirculating tumor DNA was detected in 78% (39/50) of patients. Actionable genomic alterations were identified in 36%, meeting the primary endpoint. The most frequent actionable genomic alterations included PIK3CA mutations (18%), ARID1A mutations (10%), ERBB2 amplification (6%), and ATM mutations (6%). Among 18 patients with paired tissue and circulating tumor DNA data, 66.7% showed changes in actionable genomic alterations between the primary tumor and recurrence. New actionable alterations, including ERBB2 amplifications and PIK3CA mutations, were identified exclusively in circulating tumor DNA at recurrence.
conclusionsA circulating tumor DNA analysis effectively captured genomic evolution at recurrence, identifying clinically relevant alterations not found in primary tumor tissue. These findings support the integration of a liquid biopsy into clinical practice to guide treatment for recurrent gastric or gastroesophageal junction cancer.
Indexed as
Identifiers
40889068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.